Beijing Bohui Innovation Biotechnology Group Co (SZSE:300318) Short-Term Debt & Capital Lease Obligation : ¥669.2 Mil (As of Mar. 2025)

View and export this data going back to 2012. Start your Free Trial

What is Beijing Bohui Innovation Biotechnology Group Co Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Beijing Bohui Innovation Biotechnology Group Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥669.2 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Beijing Bohui Innovation Biotechnology Group Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥704.5 Mil.

Beijing Bohui Innovation Biotechnology Group Co Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Beijing Bohui Innovation Biotechnology Group Co's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Bohui Innovation Biotechnology Group Co Short-Term Debt & Capital Lease Obligation Chart

Beijing Bohui Innovation Biotechnology Group Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

483.05

462.75

456.72

427.84

624.27

Beijing Bohui Innovation Biotechnology Group Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															549.18	531.94	413.98	624.27	669.19

Beijing Bohui Innovation Biotechnology Group Co Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Beijing Bohui Innovation Biotechnology Group Co Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Beijing Bohui Innovation Biotechnology Group Co's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Bohui Innovation Biotechnology Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Bohui Innovation Biotechnology Group Co Ltd (SZSE:300318) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

Block G Jingxinyuan, NO.25 Jia Beiwucun Road, Haidian, Beijing, CHN, 100097

Website

http://www.bohui-tech.com

Beijing Bohui Innovation Biotechnology Group Co Ltd is a high-tech biomedical enterprise integrating R&D, production, sales, and after-sales service. The company focuses on the research and development, production, sales, and after-sales services of in vitro diagnostic products. The Company's business involved two segments: inspection and testing and biological products. The Biological segment generated the majority of its revenue which engaged in the research and development, production, and sales of blood products, the product range covers human blood albumin, human immunoglobulin, and human coagulation factor three categories of multiple varieties, basically covering the important varieties of blood products.

Executives

Niu Shu Hui	Executives
Di Xiao Feng	Director
Yang Qi	Director
Lu Xin Qun	Directors, executives
Zhang Lei	Director
Wan Zhang Geng	Executives
Song Rui	Directors, executives

Beijing Bohui Innovation Biotechnology Group Co Headlines

No Headlines